Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haloxyfop-P is the most active enantiomer of the racemic herbicide haloxyfop, belonging to the aryloxyphenoxypropionic acid class. It is primarily used as a selective systemic herbicide for post-emergence control of annual and perennial grass weeds in broadleaf crops such as soybeans, cotton, canola, peanuts, and vegetables. Haloxyfop-P acts by inhibiting acetyl-CoA carboxylase (ACCase), an enzyme essential for fatty acid synthesis in grasses. This inhibition disrupts lipid metabolism and leads to growth arrest in susceptible grass species while sparing broadleaf crops[1][2][5]. The compound is typically applied as its methyl or ethoxyethyl ester proherbicides (notably "haloxyfop-P-methyl"), which are absorbed through leaves and roots and translocated throughout the plant to target meristematic tissues[1][5]. Developed originally for agricultural weed management, it has also been studied for its toxicological effects on non-target organisms[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on haloxyfop-P.